Clinical trial
Doxil Topotecan Doublet Cancer Study
NCT00252889 · Christiana Care Health Services, Other · Completed
Key facts
| NCT number | NCT00252889 |
|---|---|
| Title | Doxil Topotecan Doublet Cancer Study |
| Official title | GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in Patients With Advanced Solid Tumors |
| Lead sponsor | Christiana Care Health Services, Other |
| Collaborators | Johnson & Johnson Industry GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer |
| Intervention type | Drug |
| Interventions | Topotecan and pegylated doxorubicin |
| Enrollment | 20 |
| Start date | May 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Jun 1, 2008 |
| First posted | Nov 15, 2005 |
| Last update posted | Jan 27, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: